InMatrico®
Tissue-specific extracellular matrix kits and assays for predictive disease modeling and drug testing
Technology
Tissue-specific decellularized ECMs
Predictive results consistent with those in patients: TissueSpec® dECMs enable physiologically-relevant disease modeling and drug testing in matrico by providing the tissue-specific biochemical and mechanical ECM signals lacking in vitro.
Primary tissues
Tissues are comprised of cells attached to ECM.
Tissue-specific dECMs
Tissue decellularization (cell removal) yields tissue-specific decellularized ECM (dECM).
TissueSpec® dECM Kits
Decellularized ECM (dECM) is processed into dECM coating and hydrogel kits.
Primary tissues are decellularized using proprietary protocols to obtain tissue-specific decellularized ECMs (dECM), which are then processed into quality-controlled, ready-to-use TissueSpec® dECM Coating and Hydrogel Kits.
International Distributors
Explore the map to find distributors near you.
News
Read more
Sept. 6, 2022
Choosing Extracellular Matrix for Cultured Cells
Read more
April 5, 2022
Xylyx Bio collaboration reveals new insights into tumor drug resistance
Read more
Sept. 2, 2021
Xylyx Bio Awarded $2.2M NIH SBIR Fast-Track Grant from National Heart, Lung, and Blood Institute
Read more
Aug. 21, 2021